Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT07424833
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Phase 1 · China, United States · 6 sites
Registry update: 15 Oct 2026
NCT07494565
Recruiting
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Phase 2 · China · 1 site
Registry update: 22 Jul 2026
NCT05544968
Recruiting
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Phase 1 · United States · 1 site
Registry update: 3 Apr 2026
NCT07680933
Recruiting
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 · China · 1 site
Registry update: 2 Jul 2026
NCT07042438
Recruiting
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Phase 2 · United States · 1 site
Registry update: 5 Mar 2026
NCT07397832
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Phase 2 · China · 1 site
Registry update: 29 Jul 2026
NCT07121946
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · United States · 6 sites
Registry update: 24 Jul 2026
NCT07188558
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Phase 3 · Australia, Canada, United States · 44 sites
Registry update: 4 Nov 2026
NCT07195916
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · Australia, Belgium, Denmark, Italy, United States · 22 sites
Registry update: 9 Oct 2026
NCT06919939
Recruiting
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 15 Oct 2026
NCT07368270
Recruiting
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 · China · 1 site
Registry update: 28 Jan 2026
NCT07499271
Recruiting
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2 · China · 1 site
Registry update: 30 Mar 2026
NCT06323447
Recruiting
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Not applicable · Spain, United States · 6 sites
Registry update: 3 Nov 2026
NCT07288879
Recruiting
DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2 · Japan · 5 sites
Registry update: 8 Jan 2026
NCT07097363
Recruiting
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2 · United States · 1 site
Registry update: 21 Oct 2026
NCT07255963
Recruiting
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Phase 2 · China · 1 site
Registry update: 1 Dec 2025
NCT07189065
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · China · 41 sites
Registry update: 16 Dec 2025
NCT07371923
Recruiting
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Phase 2 · China · 1 site
Registry update: 28 Jan 2026
NCT07062627
Recruiting
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Phase 2 · South Korea · 1 site
Registry update: 17 Dec 2025
NCT07197307
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 · Germany, Italy · 39 sites
Registry update: 30 Jul 2026

Ordered by registry start date. Freshness and sponsorship never change the order.